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Genetic and phenotypic heterogeneity and the lack of sufficiently
large patient cohorts pose a significant challenge to understanding
genetic associations in rare disease. Here we identify Bsnd (alias
Barttin) as a genetic modifier of cystic kidney disease in Joubert
syndrome, using a Cep290-deficient mouse model to recapitulate
the phenotypic variability observed in patients by mixing genetic
backgrounds in a controlled manner and performing genome-wide
analysis of these mice. Experimental down-regulation of Bsnd in the
parental mouse strain phenocopied the severe cystic kidney pheno-
type. A common polymorphism within human BSND significantly
associates with kidney disease severity in a patient cohort with
CEP290 mutations. The striking phenotypic modifications we de-
scribe are a timely reminder of the value of mouse models and
highlight the significant contribution of genetic background. Fur-
thermore, if appropriately managed, this can be exploited as a pow-
erful tool to elucidate mechanisms underlying human disease
heterogeneity.
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Rare disease represents a healthcare burden estimated to af-fect ∼350 million people worldwide (1). Phenotypic vari-
ability is a confounding factor in understanding genetic disease
and often results from the underlying background genetics. The
concept of modifying genes that have little or no effect on a
phenotype in isolation but can alter the phenotype of a particular
mutation was recognized a century ago in Drosophila (2) and
subsequently shown to be an important factor in human disease
(3). While the identification of modifying genes has been sim-
plified by developments in genome-wide analyses and the avail-
ability of increasingly large patient cohorts (4, 5), genetic
modifiers in rare disease remain inherently intractable due to the
scarcity of patients.
Defects of the primary cilium result in a number of syndromes,
collectively known as ciliopathies, that exemplify the challenges
faced when attempting to understand genotype–phenotype het-
erogeneity in rare disease (6–8). Joubert syndrome is regarded as
the archetypal ciliopathy, with one of the most common causes
being biallelic mutations in the CEP290 gene (9, 10). However,
mutations in CEP290 can result in a phenotypic spectrum (11–17)
ranging from retinal degeneration alone (Leber congenital am-
aurosis) to embryonic lethality (Meckel–Gruber syndrome). In
many cases, phenotypic variability is evident among patients har-
boring identical mutations, with no clear genotype–phenotype
correlations.
Recently, the mouse has been shown to provide a good model
for numerous ciliopathies and these models have begun to
elucidate the underlying mechanisms of these diseases (18–21).
Furthermore, there is evidence to suggest that murine cili-
opathy phenotypes are influenced by genetic modifiers. The
Cep290Gt(CC0582)Wtsi mouse, for example, which presents with reti-
nal degeneration, slowly progressing cystic kidney disease, and hy-
drocephalus on a 129/Ola genetic background, is embryonic lethal
on a C57BL/6 background and shows a variable phenotype ranging
from embryonic lethality to severe cystic kidney disease on a 129/Sv
genetic background (19). This heterogeneity is indicative of the
presence of strain-specific genetic modifiers of the phenotype and
is consistent with the heterogeneity seen in CEP290 ciliopathy
patients.
Results and Discussion
In order to identify potential loci modifying murine Joubert
syndrome and establish whether mouse genetics could provide a
convenient way of identifying modifier genes in rare human dis-
eases more generally, we intercrossed Cep290Gt(CC0582)Wtsi mice
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(a hypomorphic allele, MGI:3870362; hereafter referred to as
Cep290Gt mice) to mix their genetic background in a controlled
manner (Fig. 1A). Heterozygous Cep290Gt first generation (F1)
(129/Ola x C57BL/6) animals were bred to generate homozy-
gous Cep290Gt/Gt F2 mice that were analyzed at 3 wk of age. The
number of homozygous mutant mice recovered from these crosses
deviated significantly from the expected Mendelian ratio (χ2, P <
0.005), suggesting that ∼40% of homozygous animals died in
utero, consistent with previous reports (22, 23). Viable homozy-
gous animals tended to be smaller than littermates (6.6 vs. 11.6 g
at postnatal day 21; SI Appendix, Fig. S1B), displaying varying
degrees of cranial doming, a feature associated with hydroceph-
alus (SI Appendix, Fig. S1A).
Retinal abnormalities were observed in homozygous
Cep290Gt/Gt F2 mice, similar to the phenotype previously de-
scribed for the inbred (129/Ola) strain (19), with complete loss of
the outer segment of the photoreceptor layer in all homozygous
mutant animals (SI Appendix, Fig. S1C). This suggests that the
photoreceptor phenotype is not affected by genetic modifiers,
given that it is severe in both the genetic backgrounds we have
studied. Variability in the extent of cell loss within the outer and
inner nuclear and plexiform layers was observed but showed no
consistent trends across the cohort, and association analyses
revealed no genetic associations (SI Appendix, Fig. S2 E and F).
It should be noted that at the time point of phenotyping (P21),
retinal development is ongoing and therefore the observed var-
iability may be in part due to differences in rates of development.
Homozygous F2 Cep290Gt/Gt mice displayed hydrocephalus, as
previously reported for the inbred (129/Ola) strain (19). How-
ever, high-resolution ex vivo MRI (in a subset of animals)
revealed structural defects within the cerebellum (Fig. 1 B and C
and SI Appendix, Fig. S1D) that are not found in mutant mice on
a 129/Ola genetic background, indicating that the phenotype of
the Cep290Gt/Gt Joubert syndrome mouse can be modified to
include cerebellar aplasia phenotypes typical of patients by al-
teration of the genetic background. Cerebellar lobule-specific
defects observed include hypoplasia of the folium–tuber vermis
(lobule VII) and pyramus (VIII), with some mice also displaying
additional degeneration within the uvula (IX) and nodulus (X).
It is noteworthy that mutant mice with structural abnormalities
of the nodulus (X), which forms part of the vestibulocerebellum
and is crucial for maintaining balance, displayed overt symptoms
of ataxia, a common feature of Joubert syndrome patients (10,
24, 25). It should be noted that the presence of foliation defects
did not correlate with the degree of hydrocephalus, suggesting
that additional, tissue-specific, phenotypic modifiers exist.
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Fig. 1. Phenotypic spectrum of an F2 Cep290Gt/Gt mouse model of Joubert syndrome. (A) Schematic showing mouse breeding strategy. Cep290Gt/+ het-
erozygous mice on a 129/Ola background were bred with wild-type C57BL/6 mice to generate F1 hybrids. F1 Cep290Gt/+ heterozygous mice were then in-
terbred to give F2 Cep290Gt/Gt homozygous animals with a randomized set of alleles from both parent strains. Representative alleles from 129/Ola and C57BL/
6 mice are shown in yellow and blue, respectively. Variable coat colors in F2 mice from this cross are shown including black, chinchilla, albino, and agouti (Left
to Right). (B) High-resolution ex vivo MRI showing morphologically aberrant cerebellar structures in P21 F2 Cep290Gt/Gt mice. A subset of F2 Cep290Gt/Gt mice
shows localized aplasia within the cerebellum, specifically within the folium–tuber vermis, pyramus, uvula, and nodulus (lobules VII to X, respectively; blue
overlay). Lobules I to VI appear largely unaffected (red overlay); flattening of the cerebellum against the skull can be observed in all Cep290Gt/Gt animals as a
result of hydrocephalus. Representative images of wild-type control, mild, and severe animals are shown. (Scale bar, 1 mm.) (C) Quantification of the sagittal
cross-sectional area of lobules I to VI compared with VII to X of the cerebellum in mild and severe F2 Cep290Gt/Gt animals (Student’s t test, **P < 0.01; ns, not
significant). (D) Hematoxylin and eosin (H&E) and Masson’s Trichrome images of kidneys from F2 Cep290Gt/Gt mice showing a large degree of phenotypic
heterogeneity in terms of the number and size of cysts, as well as the amount of interstitial fibrosis as indicated by increased collagen deposition (blue
staining). (Scale bars, 1 mm [main images] and 100 μm [expanded views].) (E) Immunofluorescence staining of P21 mouse kidney from F2 Cep290+/+ and
Cep290Gt/Gt animals, showing the expression of the ciliary GTPase Arl13b (green) and the water channel Aquaporin 2 (Aqp2; magenta). The 2 Lower in each
column are magnified regions from the Upper identified by dotted boxes. (Scale bars, 10 μm.) (F and G) Quantification of cilia length (F) and tortuosity (G) in
F2 Cep290+/+ and Cep290Gt/Gt animals (1-way ANOVA, *P < 0.05, **P < 0.01, ***P < 0.001).
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While the majority of homozygous mutant kidneys appeared
grossly normal, several were pale and enlarged, resembling the
kidney previously reported from a Cep290Gt/Gt mouse bred on a
mixed C57BL/6J-129/SvJ background (23). Renal histopathology
revealed a striking variability in cystic burden ranging in severity
from a few small cysts to multiple large cysts with early stages of
fibrosis and collagen deposition typical of nephronophthisis (Fig.
1D and SI Appendix, Fig. S1E). In order to avoid bias, cystic burden
was quantified in an automated way to give a “cystic index” value
that enabled the severity of kidney disease to be ranked from 0 to
52%, with the majority of animals (n = 66) falling in the 0 to
5% range (SI Appendix, Figs. S1F and S4). There was no
correlation between cystic index of the kidneys and retinal layer
loss (SI Appendix, Fig. S1G), while the most severe cerebellar
disease was associated with severe cystic kidney disease (SI Ap-
pendix, Fig. S1H).
CEP290, a transition-zone protein, has been shown to be re-
quired for normal cilia morphology in both human and mouse
(19, 26–28). Immunofluorescence staining for Arl13b, a GTPase
which is spatially restricted to the ciliary membrane, revealed
elongated primary cilia in all F2 homozygous mutant kidneys
compared with wild-type littermates (Fig. 1 E and F). Costaining
with Aquaporin 2 (Aqp2), a water channel found at the apical
surface of principal cells of the collecting duct, revealed that
cysts containing elongated cilia were found predominantly in the
distal part of the nephron (Fig. 1E). Kidneys with the highest
cystic index, however, presented with significantly longer cilia
than those with a low cystic index, and a strong association was
observed between cilia length and average cyst size (R2 = 0. 82,
P < 0.0001; SI Appendix, Fig. S1I). Cilia from kidneys with a high
cystic index also displayed increased tortuosity (Fig. 1 E and G
and SI Appendix, Fig. S1J), consistent with the elongated, tor-
tuous cilia seen in Joubert syndrome patient renal biopsies (28).
Furthermore, epithelial cells of the collecting duct showed an
almost complete loss of Aqp2 expression from the apical surface
in kidneys from the most severely affected animals (Fig. 1E).
Given that our cohort of F2 mutant mice presented with a
range of phenotypes consistent with the presence of strain-specific
modifier loci, we designed a panel of 932 informative single-
nucleotide polymorphisms (SNPs; of which 789 subsequently
passed quality control) across the genome (SI Appendix, Fig. S2A)
to distinguish between 129/Ola and C57BL/6 strains to allow
identification of potential modifiers. Seventy-seven mice were
genotyped in this way with a call rate of 96.3% (at an average
resolution of 2 to 3 Mb). The average number of recombination
events across the population of homozygous Cep290Gt/Gt mice was
39, which was invariant across the cystic kidney phenotypic range
(SI Appendix, Fig. S2 C and D). The approach was first validated
using coat color as a variable trait. As predicted, strong associa-
tions were identified in mice with black coat color (homozygosity
for the nonagouti locus) on chromosome 2 (Fig. 2 A and B) and
mice with albino/chinchilla coat color (homozygosity for the ty-
rosinase locus) on chromosome 7 (Fig. 2 C and D), thus con-
firming that our experimental approach was capable of identifying
known genetic associations.
Similar to Joubert syndrome patients, the most striking phe-
notypic heterogeneity in our mouse cohort was the severity of
kidney disease. We therefore sought to identify a modifier locus
associated with an increased potential of developing cystic kid-
ney disease in our Cep290Gt/Gt mice. Using the cystic index of the
kidneys as a continuous variable trait with a recessive pattern of
inheritance, a strong association with a single locus on chromo-
some 4, delineated by rs3664701 and rs3659850, was identified
(Fig. 2 E and F and SI Appendix, Fig. S2B). All mice with a severe
kidney phenotype (11 animals with cystic index >10%; Fig. 2)
were homozygous for SNPs inherited from the C57BL/6 back-
ground. A single mouse homozygous for C57BL/6 fell below the
10% threshold but was ranked the next most severe with a cystic
index of 7.1%, whereas all other mice were either homozygous or
heterozygous for 129/Ola–inherited SNPs and displayed a mild
kidney phenotype (65 animals). The size of this locus is 5.075 Mb
and corresponds to ∼0.18% of the mouse genome. The deviation
from Hardy–Weinberg equilibrium was determined for each lo-
cus across the genome (Fig. 2 G and H), revealing that only the
Cep290 locus on mouse chromosome 10 showed any deviation.
This is to be expected, as all mice were selected as homozygous
for the Cep290 mutation that was initially introduced into 129/
Ola mouse embryonic stem cells (19).
Having identified a locus modifying the severity of kidney
disease in murine Joubert syndrome, we went on to investigate
loci associated with the severity of renal disease in Joubert syn-
drome patients. Initially, a cohort of 6 patients was assembled, 3
with early-onset end-stage renal disease (ESRD) and 3 with mild/no
renal involvement, selected on the basis of having identical causa-
tive mutations in CEP290 [homozygous c.5668G>T; p.(Gly1890*)].
A whole exome-wide search of variants segregating with disease
severity in these patients revealed over 300 potential modifier loci
associating with kidney disease. However, selecting only loci within
the region syntenic to the mouse modifier locus (human chromo-
some 1p32) resulted in SNPs associated with severe kidney disease
in Joubert syndrome patients linked to just 2 adjacent genes—
BSND (rs2500341) and TMEM61 (rs2253466) (Table 1).
TMEM61 is reported to be expressed in a tissue-specific
manner, with the highest RNA levels in glandular tissues such as
endocrine (parathyroid), salivary, and seminal vesicle, with lower
levels found in kidney; however, there are insufficient data to re-
liably annotate protein expression in human (https://www.proteinatlas.
org/ENSG00000143001-TMEM61/tissue), while mouse Tmem61
is annotated as a lincRNA.
BSND encodes Barttin, a subunit of the chloride channels
CLCNKA and CLCNKB, essential for renal salt reabsorption that
has previously been shown to cause Bartter syndrome with senso-
rineural deafness (29). In mouse kidney, Bsnd is expressed in the
thin limb and the thick ascending limb of the loop of Henle (29)
and intercalated cells of the cortical collecting duct (30) (SI Ap-
pendix, Fig. S3A). Of note, Barttin expression is found in small cysts
of homozygous F2 mutant mice but appears to be lost in large cysts
(SI Appendix, Fig. S3A). Bartter syndrome patients with BSND
mutations have reduced urine-concentrating capacity, resulting in
increased urine production (polyuria) and chronic kidney disease
which may progress to ESRD (31, 32), as do Joubert syndrome
patients with renal involvement (nephronophthisis) (33, 34). It is
noteworthy that the mutations in CFTR encoding an apical chloride
channel may also modify cystic kidney disease phenotypes in pa-
tients with autosomal dominant polycystic kidney disease, high-
lighting the importance of chloride transport in cyst expansion (35).
rs2500341 is located within the 5′ UTR of BSND and the variant
associated with severity of kidney disease (G) has a frequency of
0.595 within 1000Genomes (global) (https://www.internationalgenome.
org) but is markedly more prevalent in European (G = 0.759)
and American (G = 0.70) populations. In addition, rs2500341 is
annotated as an eQTL, with the G allele linked with lower
levels of BSND expression within the brain (https://gtexporta-
l.org/home/). Coupled with the reduced expression observed in
the most severely affected mouse kidneys, we hypothesized that
lower expression of Bsnd from the C57BL/6 locus could be
responsible for increased cystic disease. To test this hypothesis, we
sought to determine the consequences of reducing Bsnd expression
in pure, inbred 129/Ola homozygous mutant Cep290Gt/Gt mice
(Fig. 3A). Systemic administration, via tail vein injection, of a
Bsnd antisense oligonucleotide (ASO) targeting the trans-
lational start site over 12 d resulted in a significant reduction in
Bsnd protein levels within the kidney (Fig. 3B and SI Appendix,
Figs. S3C and S5A). Immunohistochemical analysis revealed loss
of Aquaporin 2 in principal cells of the cortical collecting duct
and primary cilia with increased tortuosity, compared with control
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129/Ola Cep290Gt kidneys (Fig. 3 C and D). Injection of Bsnd ASO
in wild-type 129/Ola mice did not produce any ciliary phenotype (SI
Appendix, Fig. S5B), consistent with the concept of a genetic
modification that has little or no phenotypic effect in isolation.
These data indicate that reduction of Bsnd within kidneys of pure
129/Ola Cep290Gt/Gt mutant mice phenocopies the severe F2 mice
that are homozygous for C57BL/6–derived Bsnd. Furthermore,
immunohistochemical analysis of a Joubert syndrome patient
(NPH621: G/G at rs2500341; SI Appendix, Table S1) kidney biopsy
at ESRD reveals a remarkably similar phenotype to the mouse
models (both Bsnd knockdown in 129/Ola and severe F2 mutant
Cep290Gt/Gt), including loss of Aquaporin 2 expression and elon-
gated, tortuous primary cilia (Fig. 3E). A reduction of Barttin
expression in epithelial cells lining the cysts in kidney tissue from
patient NPH621 can also be seen (SI Appendix, Fig. S3B), con-
sistent with the findings observed in F2 Cep290Gt/Gt mice.
Having identified Bsnd as a modifier gene for the renal
manifestation of murine Joubert syndrome and observed con-
firmatory evidence in a patient biopsy, we extended our analysis
in humans to assess the relevance of this finding in a wider cohort
of CEP290 ciliopathy patients with variable phenotypes (SI Ap-
pendix, Table S1). Patients were defined as having a high severity
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score of kidney disease if they had either progressed to ESRD or
were shown to have multiple cysts within their kidneys. In all 11
CEP290 ciliopathy patients with absent/mild kidney disease phe-
notypes, we did not observe the “severe” (G/G) BSND haplotype at
rs2500341, whereas 12/18 patients with severe kidney disease
phenotypes were homozygous for this common variant (Fisher’s
exact test, n = 29, P = 0.00002), indicating a significant association
between rs2500341 and severity of kidney disease phenotype.
This study describes the first steps toward elucidating the seem-
ingly intractable phenotypic heterogeneity observed in ciliopathy
patients and, while the association we have revealed is not 100%
discriminatory for kidney disease severity in Joubert syndrome, it
lays the foundations for increasing our understanding of the het-
erogeneity of ciliopathies. We have revealed patient phenotypes at
the cellular level in unprecedented detail, and confirmed the im-
portance of mouse models, highlighting the need for consideration
of genetic background effects. Furthermore, we have demonstrated
that with the a priori knowledge afforded by mouse genetics, it is
possible to discover genetic association in rare diseases within small
cohorts of patients.
The striking phenotypic modifications observed in our F2 animals
serve as a timely reminder of the value of mouse models but also of
the potentially confounding effects resulting from genetic back-
ground. If appropriately managed, however, these effects can be
exploited, providing a powerful tool to approach human disease
heterogeneity.
Materials and Methods
Further information can be found in SI Appendix, Figs. S1–S6, and Table S1.
Statistics. All individual tests of numerical data were performed using an
unpaired Student’s t test or a 1-way ANOVA followed by a Bonferroni-
corrected post hoc test when comparing 2 or more groups. A P value of
less than 0.05 was considered statistically significant.
Study Approval. Ethical approval was obtained from the National Research
Ethics Service Committee North East (14/NE/1076), United Kingdom. All animal
experiments were performed under licenses granted from the Home Office
(UnitedKingdom) in accordancewith theguidelines and regulations for the care
anduse of laboratory animals outlinedby theAnimals (Scientific Procedures) Act
1986, and conducted according to protocols approved by the Animal Ethics
Committee of Newcastle University and the Home Office, United Kingdom.
Subjects. We obtained DNA samples (blood/saliva) after obtaining informed
consent from individuals with Joubert syndrome (with and without renal
involvement) and Leber congenital amaurosis. Criteria for Joubert syndrome
were based on the presence of cerebellar vermis aplasia/hypoplasia and/or
molar tooth sign on brain MRI. Leber congenital amaurosis/retinal de-
generation was diagnosed by an ophthalmologist. The diagnosis of renal
disease was based on clinical course and renal ultrasound scan results.
Data Availability. We declare that all data supporting the findings of this
study are available within the article, SI Appendix.
Table 1. Common SNPs in BSND and TMEM61 are associated with increased kidney involvement in Joubert syndrome patients with
CEP290 mutations
Sample
CEP290
mutation 1
CEP290
mutation 2 Kidney phenotype
Kidney
disease score†
rs2500341
MAF (C) 0.24
rs2253466
MAF (C) 0.39
F394 c.5668G>T; c.5668G>T; Enlarged cystic kidneys High GG TT
p.(Gly1890*) p.(Gly1890*) ESRD age 12 y
F700 c.5668G>T; c.5668G>T; Bilateral small hyperechogenic kidneys High GG TT
p.(Gly1890*) p.(Gly1890*) ESRD age 11 y
F944 c.5668G>T; c.5668G>T; Bilateral small hyperechogenic kidneys High GG TT
p.(Gly1890*) p.(Gly1890*) ESRD age 13 y
B1106 c.5668G>T; c.5668G>T; Hyperechogenic kidneys Low CG CT
p.(Gly1890*) p.(Gly1890*) CKD stage 2, age 10 y
F02 c.5668G>T; c.5668G>T; Hyperechogenic kidneys Low CG CT
p.(Gly1890*) p.(Gly1890*) CKD stage 1, age 15 y
A1188 c.5668G>T; c.5668G>T; Hyperechogenic kidneys Low CG CT
p.(Gly1890*) p.(Gly1890*) CKD stage 1, age 11 y
†Patients were scored based on their level of kidney function and the presence of cysts in the kidneys as shown by renal ultrasound scanning. A high disease
score indicates limited or no residual kidney function and/or the presence of multiple cysts within the kidney. CKD, chronic kidney disease; ESRD, end-stage
renal disease; MAF, minor allele frequency. Genotype is denoted as GG, TT, CG, or CT; where G is guanine, T is thymine, and C is cytosine.
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Fig. 3. Down-regulation of Bsnd in mouse recapitulates the human kidney
phenotype. (A) Schematic showing the injection schedule of Cep290Gt/Gt
animals from a 129/Ola background. Mice were i.v. injected with an anti-
sense oligonucleotide (ASO) targeted against the Bsnd gene, which codes for
the CLC-type chloride channel accessory protein Barttin. (B) Western blot of
murine kidney showing the reduction in Barttin protein level following
knockdown with Bsnd ASO. (C) Immunofluorescence images of P21 mouse
kidney from F2 Cep290Gt/Gt animals on a 129/Ola background showing the
expression of Arl13b (green) and Aqp2 (magenta) following injection of an
ASO targeted against Bsnd. (Scale bars, 5 μm.) (D) Quantification of cilia
tortuosity in Cep290+/+ and Cep290Gt/Gt animals (Student’s t test, *P < 0.05).
(E) Immunofluorescence images showing the expression of Arl13b (green)
and Aqp2 (magenta) in a section of a kidney biopsy from a Joubert syn-
drome patient (NPH621: G/G at rs2500341; SI Appendix, Table S1) with end-
stage renal disease secondary to mutations in CEP290. (Scale bars, 10 μm.)
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